Related Experiment Videos
Scintiscans and carcinoid tumors
B Carnaille1, M Nocaudie, F Pattou
1Department of General and Endocrine Surgery, University Hospital, Lille, France.
Background:
The presence of somatostatin receptors on carcinoid tumors mediates imaging of tumor extent and inhibition of tumor growth and marker secretion. This prospective study aimed to evaluate radiolabeled somatostatin analog scans in the therapeutic workup of carcinoids.
Methods:
Twenty-one patients with carcinoids underwent 26 scans with iodine octreotide or indium pentetreotide. The results for tumor and metastases imaging were analyzed and compared with those of a short inhibition test of marker secretion and with those of metaiodobenzylguanidine scan.
Results:
The sensitivity for obtaining images of the overall 43 tumor sites was 72%. We had no false-positive results. Unknown tumor sites were discovered in three patients. The results were slightly better with indium pentetreotide and metastases imaging. A positive scan did not always preclude responsiveness to the functional effect of octreotide. Results of somatostatin analog scans were better than those with metaidobenzylguanidine. The two techniques were complementary in one patient.
Conclusions:
The choice of treatment for patients with carcinoid tumors should benefit from functional inhibition test with octreotide and from indium pentetreotide and metaidobenzylguanidine scans.
Insights
Somatostatin analog scans effectively image carcinoid tumors and metastases, aiding treatment decisions. Indium pentetreotide scans showed slightly better results than iodine octreotide for carcinoid imaging.
Area of Science:
- Nuclear medicine
- Oncology
- Endocrinology
Background:
- Somatostatin receptors on carcinoid tumors are key targets for imaging and therapy.
- Radiolabeled somatostatin analogs offer potential for visualizing tumor extent and inhibiting growth.
- This study evaluated the role of these analogs in the management of carcinoid tumors.
Purpose of the Study:
- To assess the efficacy of radiolabeled somatostatin analog scans (iodine octreotide, indium pentetreotide) in the therapeutic workup of carcinoid tumors.
- To compare the diagnostic performance of these scans with functional inhibition tests and metaiodobenzylguanidine (MIBG) scans.
- To determine the utility of these imaging modalities in identifying tumor sites and metastases.
Main Methods:
- Prospective evaluation of 26 scans in 21 patients with carcinoid tumors.
- Utilized iodine octreotide and indium pentetreotide for imaging.
- Compared scan results with marker secretion inhibition tests and MIBG scans.
Main Results:
- Somatostatin analog scans achieved 72% sensitivity in imaging 43 tumor sites with no false positives.
- Indium pentetreotide demonstrated slightly superior performance for metastases imaging.
- Scans identified previously unknown tumor sites in three patients.
- Results indicated somatostatin analog scans outperformed MIBG scans, with complementarity observed in one case.
Conclusions:
- Functional inhibition tests with octreotide, alongside indium pentetreotide and MIBG scans, are valuable for guiding carcinoid tumor treatment.
- Somatostatin analog imaging provides crucial information for therapeutic planning in carcinoid patients.
- The combination of imaging and functional tests enhances the comprehensive management of carcinoid disease.